Limited options exist for inhibitors targeted against melanoma tumors with mutation subtypes other than BRAF. We investigated the cytotoxic activity of mitoquinone MitoQ), an antioxidant and ubiquinone derivative, on various human melanoma cell lines, alone or in combination with other agents to perturb cellular bioenergetics. This lipophilic cation crosses the cell membrane, enters and accumulates in the mitochondria where it can disrupt mitochondrial function at micromolar concentrations or act as an antioxidant to preserve membrane integrity at nanomolar concentrations. Consistent with previous studies, cells treated with . μM MitoQ show signiicantly reduced viability versus control treatments. Although all melanoma cells were susceptible to cytotoxicity induced by MitoQ, cells with wild-type BRAF were responsive to lower doses, compared to cells with activating mutations in BRAF. Mechanistically, the positively charged lipophilic moiety of the MitoQ induced a dose-dependent collapse of the mitochondrial membrane potential Δψm) and signiicantly reduced the mitochondrial ATP production and reduced oxygen consumption rate, suggesting mitochondrial dysfunction. We also combined MitoQ with a glycolytic lactate dehydrogenase A inhibitor FX-) and observed an enhanced reduction in viability, but not other therapies examined. To summarize, the data suggest that FX-enhances the cytotoxic efects of MitoQ in cells with wild-type BRAF.
. Introduction
Mitoquinone MitoQ) is a synthetic compound and functional antioxidant that enters the mitochondria and accumulates there. Low doses thwart lipid peroxidation, whereas doses above μM can disrupt mitochondria membrane integrity [ , ] . MitoQ has a ubiquinone moiety covalently connected through a -carbon alkyl chain to a lipophilic cation triphenylphosphonium TPP+) moiety [ , ] . Recently, this TPP+ moiety has also been shown to inhibit the mitochondrial electron transport chain and induce mitochondrial proton leak [ ].
However, additional molecular mechanisms by which these lipophilic cations induce antitumorigenic efects likely exist. Previously, such mitochondria-targeted lipophilic cations displayed cytotoxic activity against hepatocellular carcinoma and breast cancer using cell culture and/or animal models of malignancy [ ]. Unfortunately, controversy surrounds whether MitoQ can be utilized to prevent age-associated diseases, since some clinical trials showed a lack of eicacy in models outside of cancer [ , ] .
The mitochondria are the cell's powerhouse, responsible for the production of adenosine triphosphate ATP), the energy required by the cell, utilizing a process called oxidative phosphorylation. Although mechanisms of aerobic cellular respiration are far more eicient in the production of ATP, many tumorigenic cells curiously switch to anaerobic metabolism glycolysis) during malignant transformation, despite the presence of oxygen, which can be referred to as the "Warburg efect" [ ]. This abnormal reprogramming of energy metabolism is therefore a hallmark of cancer [ ]. However, not all cancer cells utilize glycolysis, which provides far less ATP, but at a much faster rate. At least prostate and breast cancers, as well as leukemias, likely require oxidative phosphorylation [ ].
Intriguingly, studies also suggest that melanoma cells are dependent upon oxidative phosphorylation and show signiicantly more oxygen consumption than their normal counterparts, the melanocytes [ ]. Alternatively, other studies suggest that melanoma cells may vacillate between utilizing either oxidative phosphorylation or glycolysis, depending on the environmental conditions [ ]. Since cells found within tumors are highly heterogenic, it is likely that both conditions could be found at diferent locations when sampling the same tumor specimen.
Malignant cells reprogram or vacillate their cellular metabolism to meet the anabolic requirements for growth and proliferation while also sustaining their survival and viability amid harsh microenvironments with limited nutrients [ ]. Among melanoma cells, this bioenergetic switch has been suggested to be a direct consequence of an oncogenic activating mutation in BRAF [ ]. This further insinuates that melanomas expressing wild-type BRAF versus mutant BRAF proteins would respond diferently to compounds that target the mitochondria. Since , the armamentarium has grown tremendously for small molecule inhibitors targeting BRAF melanomas, including vemurafenib, cobimetinib, dabrafenib, and trametinib, but there is a lack of targeted therapeutics for those cancer subtypes without the BRAF mutation.
In this study, we sought to investigate whether MitoQ has cytotoxic activity against human melanoma cell lines, both wild-type and BRAF mutant melanomas, alone or in combination with other agents to perturb cellular bioenergetics. We observed that cells treated with MitoQ have signiicantly less viability than controls and display enhanced mitochondrial dysfunction due to a decrease in mitochondrial metabolism. Our results also demonstrate that the cytotoxic efect was mediated by the positively charged lipophilic moiety of the MitoQ, sinceDecyl)triphenylphosphonium bromide dTPP) recapitulated the reduction in cell viability. Furthermore, we found that MitoQ displayed lower IC when combined with the FX-, a small molecule that inhibits lactate dehydrogenase A, compared to single agent treatment.
. ) medium supplemented with % fetal bovine serum, or without for serum-free medium, and % penicillin/streptomycin was used to culture and maintain cell lines Gibco ® and Thermo Fisher Scientiic Inc.). Cells were cultured at °C in an atmosphere of % humidity and % CO . The medium was changed every h. Cells were maintained for at least three subsequent passages after thawing prior to conducting the experiments to ensure the stability of their physiochemical properties. For the no-glucose media, we used RPMI deprived of glucose and HEPES bufer Invitrogen ® , Carlsbad, CA) that contained mM L-glutamine and was supplemented with % FBS and % penicillin/streptomycin. For the high-glucose media, we used no-glucose media above) supplemented with mM glucose. For the galactose media, we used no-glucose media above) supplemented with mM galactose. The mM glucose and galactose stock solutions were prepared by dissolving . g of glucose or galactose powders into a mL deionized water, volume to mL, and then either sterilized by autoclaving glucose solution) or iltration galactose solution) to make it suitable for cell culturing purposes.
. . Chemicals
The , and PF-), and then added to the wells to give the inal drug concentrations ranging from . to μM) using diferent conditioned media where indicated. Cells were then incubated for h and cell viability was measured using the CellTiter-Blue μM) and incubated for h in serum-free medium.
. . Mitochondrial toxicity assay
MeWo cells were plated at cells/well on standard, lat-botom, clear -well plates with a inal media volume of μL/well. After h, cells were then maintained in either high glucose or galactose media for h as previously described prior to treatment with diferent compounds. Cells were then treated with MitoQ at diferent concentrations ranging from to μM in diferent conditioned media as speciied above. In addition, cells were treated with a positive control toxic compound, digitonin μM) and then both groups were incubated for h at °C in an atmosphere of % humidity and % CO . Cellular toxicity proiles were generated using the Mitochondrial ToxGlo ™ Assay Promega Madison, WI) following the manufacturer's protocol. Next, an ATP detection reagent that consists of luciferin, ATPase inhibitors, and thermostable Ultra-Glo ™ luciferase was utilized to lyse viable cells and assess their ATP levels. This combination of reagents generates a luminescent signal proportional to the amount of ATP present.
. . Oxygen consumption rate assay
MeWo cells were seeded at , cells/well on standard, lat-botom, clear -well plates, and incubated for h. Cells were treated with increasing concentrations of MitoQ . μM) for min prior to the assessment of cellular respiration using Oxygen Consumption Rate Assay Kit MitoXpress ® -Xtra HS Method, Cayman Chemicals Ann Arbor, MI) following the manufacturer's protocol. The phosphorescent oxygen probe provided by the kit is quenched by oxygen in the extracellular medium. Therefore, the signal intensity obtained using this kit is proportional to the increase in the oxygen consumption rate by cells.
. . Assessment of the mitochondrial membrane potential Δψm
MeWo cells were plated at cells/well in standard, lat-botom, clear -well plates, and incubated for h. Cells were washed twice with warm phosphate bufered saline and the nuclei were stained using NucBlue ® live cell Hoechst stain following the manufacturer's protocol. Cells were then washed one time with warm PBS and then incubated in warm live cell imaging solution containing nM tetramethylrhodamine methyl ester TMRM) dye Molecular Probes ™ , Thermo Fisher Scientiic) for min in the dark at room temperature prior to the treatment with MitoQ . μM) or left untreated. Fluorescent imaging was performed to visualize nuclear Hoechst) and mitochondrial TMRM) staining with DAPI and TRITC ilters, respectively, using an X inverted luorescent microscope Olympus, Center Valley, PA).
. . Fluorescence images analysis
MeWo cells were viewed using an Olympus X inverted epiluorescent microscope × objective) with an ND neutral density ilter and images were captured using a DP-camera with identical black balance correction and exposure time in the CellSens Software Olympus). Fluorescence microscopy experiments were repeated three times and three random pictures per condition per experiment were used to quantify the TMRM dye luorescence intensity n = ) using Image-Pro® Insight . MediaCybernetics®, Rockville, MD). The TMRM corrected luorescence intensity was calculated for each image by normalizing the total red luorescence of each entire × image total TMRM intensity) by the number of cells in the same image determined by the number of DAPI nuclei counted by manual tag in Image-Pro® Insight) to eliminate the impact of the diferences in cell numbers between wells on our interpretation of data. Cells per image ranged from to . Average TMRM corrected intensities for each dosing condition were expressed as relative percentage of the luorescence intensities of untreated cells.
. . Statistical analysis
The statistical diferences in experimental data were analyzed using analysis of variance ANOVA) test, followed by either Tukey's or Bonferroni's multiple comparisons tests between groups using GraphPad Prism La Jolla, CA). Student's t-test was used when only two groups are compared. *p < . , **p < . , and ***p < .
indicate the levels of signiicance.
. Results
To study the cytotoxic efects of the mitochondria-targeted lipophilic cation MitoQ in melanoma cells, we treated BRAF wild-type melanoma cells, MeWo and SB-, or melanoma cells with BRAF activating mutations, A or SK-MEL-, with increasing concentrations of MitoQ .
μM) for h white bars) or h red bars). The data suggest that incubation with MitoQ during this period signiicantly suppresses the viability all cell lines in a dose-depend-ent manner Figure A) . Notably, MeWo and SB-cells are more sensitive to lower concentrations of MitoQ .
. μM at h p < . ), when compared to A or SK-MEL-cells Figure B) . We assessed cell viability h postreatment in MeWo cells with increasing concentrations . μM) of cisplatin, dacarbazine, Ki , PF-, and HAand elesclomol to evaluate the cytotoxic potency of MitoQ in comparison with other chemotherapeutics as negative controls) or investigational compounds Figure C) . MitoQ signiicantly afected cell viability at lower concentrations . μM) in MeWo cells when compared with other agents *p < . ). Since MeWo cells are more sensitive to MitoQ treatment than A or SK-MEL-cells, we used MeWo cells to examine whether the MitoQ-induced cytotoxicity of melanoma cells is resultant from dysfunctional mitochondria. For this assay, cells were treated with increasing concentrations .
μM) of MitoQ in the presence of high glucose or glucose-deprived/galactosesupplemented medium. Replacing glucose with galactose in the medium is a well-established approach to study the efect of mitochondrial toxins in cancer cells [ , ] . The purpose of this switch is to augment the susceptibility of cells to the MitoQ-mediated mitochondrial toxicity. Indeed, replacing glucose with galactose signiicantly exacerbates the cytotoxic efects of MitoQ after or h of treatment Figure A) . As a correlative, we measured the intracellular ATP levels after a h treatment with increasing concentrations of MitoQ. MeWo cells Human Skin Cancer, Potential Biomarkers and Therapeutic Targets 130 cultured in galactose-supplemented medium exhibited signiicant reduction ***p < . ) among intracellular ATP levels with MitoQ treatment Figure B) .
Figure .
Replacing cell culture medium containing glucose with galactose increases susceptibility to MitoQ-mediated cytotoxicity. To determine whether the MitoQ-induced cytotoxicity is the result of dysfunctional mitochondria, we maintained MeWo cells in high glucose mM) or galactose mM)-supplemented medium for A) or h prior to MitoQ treatment. Cells cultured in galactose-supplemented media rely on the mitochondria to generate ATP and sustain viability, which make them more suitable to mitochondrial toxicants. B) ATP levels of MeWo cells were measured using ToxGlo™ Assay after h exposure to increasing concentrations of MitoQ with cells cultured in diferent medium. C) Results are also shown as the percentage of vehicle-treated controls set at %) within experiments using the indicated concentrations of MitoQ or digitonin. D) Plasma membrane cytotoxicity was assessed using the indicated concentrations of MitoQ or digitonin. E) The viability of MeWo cells was measured in the presence of dTPP with cells cultured in either glucose black bars) or galactose red bars) for or h as indicated. Data are expressed as means ± SEM, n = per treatment group. We then assessed the cell membrane integrity using a luorogenic peptide substrate bis-AAF-R ) that measures dead-cell protease activity. This peptide cannot cross the intact cell membranes of live cells and, therefore, the luorescence signal is proportional to the non-live cells with compromised cell membranes. MitoQ treatment did not change cell membrane integrity in conditioned medium, unlike the cytotoxic compound digitonin, which is a detergent that can dissolve cell membranes, block ATP production, and subsequently cause cell death. Here, the positive control digitonin caused a signiicant reduction in ATP Figure  C) and a twofold change in the cell membrane integrity Figure D) . Taken together, these data suggest that the cytotoxicity mediated via MitoQ potently afects mitochondria however, it does not indicate the moiety responsible. Thus, we treated cells with dTPP, the positively charged lipophilic cation contained within the structure of MitoQ. Indeed, cells in galactosecontaining medium were not viable in the presence of . μM dTPP at or h Figure E) , suggesting this component is responsible for the MitoQ-induced cytotoxicity. To further conirm this mechanism, we measured the oxygen consumption rate of MeWo cells in response to acute exposure. The data show that MitoQ min to h) causes a signiicant reduction in the respiratory capacity of the mitochondria Figure A) . In addition, we assessed the impact of MitoQ on the mitochondrial membrane potential Δψm) using luorescent TMRM dye, which relects the level of mitochondrial transmembrane potential an indication of functional respiratory chain complexes. Data show the dose-dependent Figure B ) and rapid min) collapse Figure C ) of the mitochondrial membrane potential Δψm) in treated MeWo cells. Unlike staurosporine, the potent protein kinase inhibitor that is cytotoxic to mammalian tumor cell lines, which induced an apparent maximal reduction in the Δψm at diferent concentrations . μM), MitoQ caused a dose-dependent collapse of the Δψm Figure D) . These data show that MitoQ disrupted the mitochondrial respiratory chain and oxidative phosphorylation prior to decreases in cell viability, suggesting that these events lead to the subsequent melanoma cell cytotoxicity. Since melanoma cells can reprogram their metabolism toward aerobic glycolysis to survive in case of mitochondrial dysfunction, we hypothesized that inhibition of the lactate dehydrogenase A LDHA) enzyme would force the cells to rely on the mitochondria. Thus, this would increase vulnerability to MitoQ-induced cytotoxicity. Indeed, inhibition of LDHA using FXenhanced the cytotoxic efects of MitoQ among MeWo, A , SB-, and SK-MEL-cells after h of incubation Figure A) . Interestingly, the combination of MitoQ with investigational autotaxin inhibitors PFand HAfor h reduced, rather than enhanced, the cytotoxic capabilities of MitoQ Figure B) . The signiicant diference among treated groups is clearly demonstrated at . and μM Figure C) . The IC values further relect the increase in cytotoxicity with combinations between MitoQ and FX-against other comparisons Table ) . These data suggest that disruption of the cellular metabolic machinery serves as a potential cytotoxic strategy against melanoma in vitro and warrants further investigation in vivo. 
. Discussion
The data suggest that melanoma cells are susceptible to cytotoxicity mediated by the functional antioxidant, MitoQ, by inducing a dose-dependent reduction in the basal oxygen consumption rate and a rapid depolarization of the mitochondrial membrane potential. Culturing MeWo cells in galactose-supplemented medium signiicantly reduces intracellular ATP levels in response to MitoQ treatment, compared with culturing in glucose-containing medium. The data show that MitoQ did not afect the plasma membrane integrity, unlike the cell membrane permeabilizing compound, digitonin. Importantly, our study demonstrates that dual disruption of the metabolic machinery enhances the cytotoxicity of MitoQ using FX- Figure ) .
The ability of cancer cells, melanoma cells in particular, to reprogram their metabolism has emerged as a major factor that leads to the development of resistance to many existing therapeutics [ , ] . Recent studies have demonstrated that high levels of lactate dehydrogenase LDH), an enzyme that converts the cytosolic pyruvate into lactate, could be utilized as a predictor of disease progression and chemotherapy response in addition to its involvement in the resistance of diferent types of cancer cells, including melanoma cells to chemotherapeutic drugs [ , ] . Results from a recent Phase III clinical trial revealed that metastatic melanoma patients with high serum levels of LDH have shown less favorable responses to elesclomol, a promising irst-in-class mitochondria-targeted compound that exerts anticancer activity by inducing oxidative stress and subsequent apoptotic cell death [ ].
Figure . Working model of the observed treatment efects. This schematic illustration represents how targeting lactate metabolism enhances the cytotoxic efects of the mitochondria-targeted lipophilic cation MitoQ in melanoma cells. The normal cell depicted here is generating ATP through mitochondrial oxidative phosphorylation. During malignant transformation, cancer cells tend to strategically reprogram their metabolism toward aerobic glycolysis to produce lactate in order to acidify the surrounding tumor microenvironment and to survive in the harsh and metabolically limiting conditions, which is illustrated here by the cancer cell. In addition, the cancer cell is also maintaining functional mitochondria to resist apoptotic signals. The botom cell shows our working model with dual disruption of metabolic machinery using a combination of MitoQ and FX-to counteract the melanoma cell's viability.
Therefore, we hypothesized that inhibiting cellular aerobic glycolysis would create a synergistic response to the cytotoxic efects of MitoQ, an approach conducted by several studies whereby mitochondria-targeted compounds were used in combination with glycolysis inhibitor, -deoxyglucose -DG). However, due to the high concentration of -DG needed to achieve the desirable synergistic cancer cell growth arrest [ , , ], we were eager to ind a more potent and irreversible glycolysis inhibitor that could augment MitoQ's cytotoxicity. Thus, in this study we found that the cytotoxic efects of MitoQ were synergistically enhanced when combined with a subtoxic μM) concentration of FX-, a selective suppressor of lactate dehydrogenase A. These data suggest that FX--treated cells were forced to rely more on mitochondrial oxidative phosphorylation to survive, which made them more vulnerable to the efects of the lipophilic cation MitoQ. Consistent with previous studies showing that BRAF wild-type cells, including MeWo cells, display enhanced oxidative phosphorylation capabilities and mitochondrial capacity [ ], we observed that these cells are more sensitive to MitoQ treatment than A cells, which possess an activating BRAF mutation. Therefore, our study is relevant to developing targeted strategies against wild-type BRAF melanomas, which includes the subtypes RAS, NF , and Triple-WT [ ], with the most relevance to Triple-WT. Although the majority of melanoma patients have tumors with activating mutations in BRAF, and thus are candidates for BRAF inhibitors like vemurafenib, trametinib, dabrafenib, and cobimetinib, those patients that have tumors with wild-type BRAF lack a clear strategy for targeted therapy. BRAF status of melanoma cells has been directly linked to cellular metabolism and the bioenergetic switch between mitochondrial oxidative phosphorylation and aerobic glycolysis [ , ] . Given the ability of MitoQ to accumulate at large concentrations in the mitochondria [ ], it is not altogether surprising that MitoQ has a profound efect on the viability of cells with increased mitochondrial respiratory capacities. In summary, more research is needed to investigate molecular vulnerabilities among these subgroups.
